Alcon Launches Fully Personalized LASIK Treatment with wavelight plus in U.S. and Canada

Tuesday, September 9 2025 | 15 h 06 min | News

Alcon has announced the launch of wavelight® plus, the first fully personalized LASIK treatment now available in the U.S. and Canada.

Alcon describes wavelight plus as a next-generation platform offering a new level of precision in laser eye surgery. The system uses ray tracing technology powered by the Sightmap diagnostic device to create a three-dimensional “Digital Eye Twin” of each patient’s eyes, based on more than 100,000 data points. This allows surgeons to plan and deliver highly personalized procedures without the need for nomogram inputs.

According to clinical data from over 200 patients, wavelight plus demonstrated strong outcomes:

100% of myopic eyes achieved 20/20 uncorrected distance visual acuity at three months.
89% achieved 20/16, and 50% reached 20/12.5 at three months.
98% were within one line of preoperative corrected vision.
94% achieved the same or better corrected vision compared to preoperative results.

“Patients expect excellent results after surgery. Wavelight plus enables a premium, personalized treatment with a high probability of achieving outcomes beyond 20/20 vision,” said Dr. Mark Lobanoff, CEO of OVO LASIK + LENS (Minnesota).

Canadian refractive surgeon Dr. Raymond Stein, Medical Director of the Bochner Eye Institute and Professor of Ophthalmology at the University of Toronto, added: “This next-generation technology allows me to deliver refractive surgery precisely tailored to each patient’s unique optical system.”

Wavelight plus has already been introduced in China, Europe, and Asia-Pacific markets. The technology is expected to be commercially available in Canada in late 2025.